New Data Surrounding Pediatric Pneumococcal Disease Shows Promise

Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.

Pharmacy Times spoke with Luwy Musey, executive director in biologics and vaccines clinical research at Merck, about the results from two phase 3 pediatric studies surrounding pneumococcal disease that was presented at the IDWeek 2021 conference.

Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.